Prediabetes low blood sugar trial pulled before it began
NCT ID NCT05174507
First seen Feb 22, 2026 · Last updated Jun 24, 2026 · Updated 19 times
Summary
This study planned to test whether empagliflozin or anakinra could reduce low blood sugar episodes after meals in people with prediabetes. Participants would have received a single dose of one drug or a placebo before a standardized meal. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTPRANDIAL HYPOGLYCEMIA are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin and anakinra
What this could lead to
If it had worked, this could point toward a new way to treat low blood sugar after meals in people with prediabetes.
What could go wrong
The trial was withdrawn before enrolling anyone, so no data exist. Even if run, it was a small early-phase study with uncertain outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.